Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed and Double-Dose Vometinib for EGFR+ NSCLC Leptomeningeal Metastases
NCT06861218Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vometinib, pemetrexed in leptomeningeal metastases (LM), sponsored by Zhejiang Cancer Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
vometinibpemetrexed
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT06861218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861218.